Astellas and the Blood and Marrow Transplant Clinical Trials Network Report P-III Trial (MORPHO) Results of Gilteritinib for FLT3-ITD Acute Myeloid Leukemia
Shots:
- The P-III trial evaluating gilteritinib (120mg) as a maintenance therapy vs PBO in 356 patients across North America, the EU & the Asia-Pacific region, incl. Japan
- The trial showed favorable results in subgroups of FLT3-ITD mutated AML patients, incl. patients with detectable MRD & also failed to show RFS improvement in the entire cohort, clinical improvement of RFS in a subgroup of patients with detectable MRD (72.4% vs 57.4%) @2yrs.
- The exploratory analysis showed a favorable RFS for ~50% of patients with detectable MRD pre- or post-HSCT vs those without detectable MRD, the incidence of chronic GVHD (52.2% vs 42.1%). Gilteritinib is available as Xospata in the US, Japan, China & selected EU countries
Ref: PRNewswire | Image: Astellas
Related News:- Daiichi Sankyo’s Vanflyta (quizartinib) Receives the MHLW’s Approval for Newly Diagnosed FLT3-ITD Positive AML
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
